I disagree that there is nothing new.
No safety issues - positive
1 partial response very early in trial - positive, especially when these patients having no alternative available other than death!
progression to next stage of the trial - positive
The flip side is safety issues, efficacy issues no further trial.
Yes they have to report but both companies will be happy on progress I would suggest. My glass is half full.
Merry Xmas
Ann: INSIGHT-004 clinical trial update, page-16
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.060(20.3%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.5¢ | 33.5¢ | $6.427M | 18.03M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 133736 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |